Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 16/20 | 0.45 |
| ▸ | GALK1 | P51570 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723321 | 0.94 | LTC4S (0.44) | LTC4SKDM4EALDH1A1MAPT | |
| SCHEMBL238832 | 0.90 | LTC4S (0.48) | LTC4S | |
| SCHEMBL9989259 | 0.89 | LTC4S (0.53) | LTC4S | |
| SCHEMBL9989370 | 0.85 | LTC4S (0.50) | LTC4S | |
| SCHEMBL237245 | 0.79 | LTC4S (0.70) | LTC4S | |
| SCHEMBL2948416 | 0.79 | LTC4S (0.48) | LTC4SKDM4E | |
| SCHEMBL1724698 | 0.79 | LTC4S (0.46) | LTC4SKDM4EALDH1A1MAPT | |
| SCHEMBL1722593 | 0.76 | LTC4S (0.51) | LTC4S | |
| SCHEMBL1724154 | 0.75 | LTC4S (0.49) | LTC4SKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL2888878 | 0.75 | KDM4E (0.48) | LTC4SKDM4EMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | LTC4S 1/4885GALK1 1977/4885KDM4E 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.